<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04130841</url>
  </required_header>
  <id_info>
    <org_study_id>1901-159-1006</org_study_id>
    <nct_id>NCT04130841</nct_id>
  </id_info>
  <brief_title>Effects of Internal Limiting Membrane Peeling on Visual Function in Epiretinal Membrane Surgery</brief_title>
  <official_title>Effects of Internal Limiting Membrane Peeling on Visual Function in Epiretinal Membrane Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients who are diagnosed with idiopathic epiretinal membrane and scheduled to undergo
      epiretinal membrane removal will be treated with conventional vitrectomy and the epiretinal
      membrane will be removed. After removal of the epiretinal membrane, indocyanine green
      staining will be used to determine the internal limiting membrane (ILM) peeled off with the
      epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal
      limiting membrane is not peeled together, the investigators determine whether the active
      Internal limiting membrane peeling is performed by 1:1 randomization immediately during
      surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three
      groups will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epiretinal membrane recurrence</measure>
    <time_frame>12 months after the surgery</time_frame>
    <description>Recurrence of the epiretinal membrane after the surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>12 months after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M-chart</measure>
    <time_frame>12 months after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aniseikonia</measure>
    <time_frame>12 months after the surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>Spontaneous ILM peeling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active ILM peeling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No ILM peeling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Internal Limiting Membrane Peeling</intervention_name>
    <description>After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.</description>
    <arm_group_label>Active ILM peeling</arm_group_label>
    <arm_group_label>Spontaneous ILM peeling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal to or older than 19 years

          -  Patients diagnosed with idiopathic epiretinal membrane and scheduled to undergo the
             epiretinal membrane removal surgery

        Exclusion Criteria:

          -  Accompanied with retinal vascular disease or intraocular inflammation

          -  Prior treatment with vitrectomy in the study eye

          -  History of glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Un Chul Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Un Chul Park</last_name>
    <phone>82-2-2072-2438</phone>
    <email>cloudyfe@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Un Chul Park</last_name>
      <phone>82-2-2072-2438</phone>
      <email>cloudyfe@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Un Chul Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Internal limiting membrane peeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

